Can-Fite BioPharma Ltd. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Can-Fite BioPharma Ltd. (CANF) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 16.00% for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-26
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2025-12-31 | 16.00% 20-F · filed 2026-03-26 |
| 2024-12-31 | 7.50% 20-F · filed 2025-04-14 |